ES2238774T3 - Conjugados que comprenden dos agentes activos. - Google Patents

Conjugados que comprenden dos agentes activos.

Info

Publication number
ES2238774T3
ES2238774T3 ES98954603T ES98954603T ES2238774T3 ES 2238774 T3 ES2238774 T3 ES 2238774T3 ES 98954603 T ES98954603 T ES 98954603T ES 98954603 T ES98954603 T ES 98954603T ES 2238774 T3 ES2238774 T3 ES 2238774T3
Authority
ES
Spain
Prior art keywords
fibrinogen
agent
carrier
microcapsules
factor viii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98954603T
Other languages
English (en)
Spanish (es)
Inventor
Nicola Jane Church
Roy Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quadrant Drug Delivery Ltd
Original Assignee
Quadrant Drug Delivery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadrant Drug Delivery Ltd filed Critical Quadrant Drug Delivery Ltd
Application granted granted Critical
Publication of ES2238774T3 publication Critical patent/ES2238774T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES98954603T 1997-11-14 1998-11-16 Conjugados que comprenden dos agentes activos. Expired - Lifetime ES2238774T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9724143 1997-11-14
GBGB9724143.4A GB9724143D0 (en) 1997-11-14 1997-11-14 Pharmaceutical conjugate

Publications (1)

Publication Number Publication Date
ES2238774T3 true ES2238774T3 (es) 2005-09-01

Family

ID=10822123

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98954603T Expired - Lifetime ES2238774T3 (es) 1997-11-14 1998-11-16 Conjugados que comprenden dos agentes activos.

Country Status (9)

Country Link
US (1) US7001989B2 (cg-RX-API-DMAC10.html)
EP (1) EP1047452B1 (cg-RX-API-DMAC10.html)
JP (1) JP2001523648A (cg-RX-API-DMAC10.html)
AT (1) ATE293459T1 (cg-RX-API-DMAC10.html)
AU (1) AU1165899A (cg-RX-API-DMAC10.html)
DE (1) DE69829880T2 (cg-RX-API-DMAC10.html)
ES (1) ES2238774T3 (cg-RX-API-DMAC10.html)
GB (1) GB9724143D0 (cg-RX-API-DMAC10.html)
WO (1) WO1999025383A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6933366B2 (en) * 1996-12-27 2005-08-23 Tripep Ab Specificity exchangers that redirect antibodies to bacterial adhesion receptors
EP1089762A1 (de) * 1998-06-10 2001-04-11 Baxter Aktiengesellschaft Konjugat, bestehend aus einem lektin und einem blutgerinnungsfaktor
GB9825105D0 (en) * 1998-11-16 1999-01-13 Andaris Ltd Pharamaceutical conjugates
GB9827813D0 (en) * 1998-12-17 1999-02-10 Andaris Ltd Pharmaceutical conjugates
DE19926475A1 (de) * 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
WO2001008709A1 (en) * 1999-07-28 2001-02-08 Valentis, Inc. Sonoporation of tumors
GB0323378D0 (en) * 2003-10-07 2003-11-05 Univ Leicester Therapeutic agent
ES2525585T3 (es) 2006-05-05 2014-12-26 The Regents Of The University Of Michigan Intermedios para la preparación de miméticos de SMAC bivalentes
GB0623607D0 (en) 2006-11-27 2007-01-03 Haemostatix Ltd Tissue adhesive
US20090170195A1 (en) * 2007-12-28 2009-07-02 Kent State University Curcumin-hyaluronan compounds
US20110077202A1 (en) * 2008-05-16 2011-03-31 Bayer Healthcare Llc Targeted Coagulation Factors and Method of Using the Same
ES2427627T3 (es) * 2009-04-06 2013-10-31 Novo Nordisk A/S Entrega dirigida de proteínas de Factor VIII a plaquetas
GB201101740D0 (en) * 2011-02-01 2011-03-16 Haemostatix Ltd Therapeutic agents with improved fibrinogen binding

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
IL85372A (en) * 1987-02-12 1992-12-01 Us Health Penta to nona-peptides with laminin - like activity having an amino acid sequence and anti- metastatic compositions containing them
US5716614A (en) 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
DE69529917T2 (de) * 1994-12-16 2003-12-11 Elan Drug Delivery Ltd., Ruddington Vernetzte mikropartikel und ihre verwendung als arzneiträger
EP0831793A4 (en) 1995-06-06 2000-11-15 Hemosphere Inc PROTEIN PARTICLES FOR THERAPEUTIC AND DIAGNOSTIC USE
AU718956B2 (en) 1996-10-21 2000-05-04 Quadrant Healthcare (Uk) Limited Platelet substitutes and conjugation methods suitable for their preparation

Also Published As

Publication number Publication date
AU1165899A (en) 1999-06-07
EP1047452A1 (en) 2000-11-02
WO1999025383A1 (en) 1999-05-27
GB9724143D0 (en) 1998-01-14
DE69829880T2 (de) 2005-09-22
US7001989B2 (en) 2006-02-21
EP1047452B1 (en) 2005-04-20
DE69829880D1 (de) 2005-05-25
ATE293459T1 (de) 2005-05-15
JP2001523648A (ja) 2001-11-27
US20030087826A1 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
ES2232862T3 (es) Sustitutos de plaquetas y procedimientos de conjugacion apropiados para su preparacion.
ES2655639T3 (es) Conjugado de factor VIIa - ácido (poli)siálico que tiene una semivida in vivo prolongada
RU2526804C2 (ru) Конъюгированные белки с пролонгированным действием in vivo
RU2503464C2 (ru) Биогель
ES2590679T3 (es) Glicopolisialilación de proteínas diferentes a proteínas de coagulación de la sangre
US20130029913A1 (en) Artificial platelets
US20110262366A1 (en) Compounds for targeting endothelial cells, compositions containing the same and methods for their use
JP2000509394A (ja) 細胞膜を横切って物質を輸送するためのポリペプチド結合体
EP1047452B1 (en) Conjugates comprising two active agents
JP2939341B2 (ja) 赤血球代用剤
KR20040015692A (ko) 저장 안정성의 액상 피브리노겐 제형
ES2362205T3 (es) Composición farmacéutica con propiedades trombolíticas, antiinflamatorias y citoprotectoras.
JP2011520913A (ja) 標的化凝固因子およびそれを使用する方法
JP2011137044A (ja) フィブリン/フィブリノーゲン結合結合体
JP2017505298A (ja) フィブリノゲン結合ペプチドを含むペプチドデンドリマー
JP2002515447A (ja) 抑制されない血管内フィブリンクロット形成の予防および治療のための組成物および方法
US20140031293A1 (en) Therapeutic agents with improved fibrinogen binding
ES2213759T3 (es) Preparacion liquida acuosa estabilizada de factor xiii de coagulacion sanguinea.
JP2001523648A5 (cg-RX-API-DMAC10.html)
US20190240295A1 (en) Factor viii with extended half-life and reduced ligand-binding properties
WO2000035487A1 (en) Pharmaceutical conjugates comprising two active agents
AU5669499A (en) Targeting and prolonging association of drugs to the luminal surface of the pulmonary vascular endothelial cells
WO2000029028A1 (en) Pharmaceutical conjugates of glycoproteins and insoluble carriers
MXPA99003677A (en) Platelet substitutes and conjugation methods suitable for their preparation
CN1240364A (zh) 血小板替代物和适于其制备的缀合方法